RE:Phase 2 Merus founded in 2003 trades at US$58May 24, 2024 - Regeneron’s costimulatory bispecific antibody REGN7075 misses the mark in patients with advanced solid tumors in the split-phase trial, involving microsatellite stable colorectal cancer (MSS CRC), a form of cancer that has historically been unresponsive to immunotherapy.
“The presence of liver metastases is increasingly being recognized as a sign of a tougher immune suppressed environment to overcome,” Israel Lowy, M.D., Ph.D., senior vice president of translational and clinical oncology at Regeneron, told Fierce Biotech. “Since then, we actually have seen a response in a patient with a liver metastasis—it's not part of the data cut being presented.”
Analysts from Leerink Partners had hoped to see therapeutic doses inducing strong responses without a high rate of unmanageable adverse events or deaths. If achieved, Leerink Partners said its confidence would increase in Regeneron’s costimulatory bispecifics platform, a method designed to bridge T-cells to cancer cells and change CD28 signaling to boost anti-tumor activity in combination with the PD-1 inhibitor Libtayo or a CD3 bispecific.
“Microsatellite stable colorectal cancer has historically been unresponsive to immunotherapy,” Neil Segal, M.D., Ph.D., research director of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center and a trial investigator, said in Regeneron’s release. “This combination is one of the first immunotherapy regimens to show clinical activity in microsatellite stable colorectal cancer, and we are excited to advance this trial in additional tumor types.”
He also said the company thinks some of the CAR-T programs recently acquired from 2seventy bio in January may benefit from the addition of a costimulatory agent.
https://www.fiercebiotech.com/biotech/asco-much-prove-regeneron-shares-new-solid-tumor-data-egfrxcd28-bispecific